A Novel and Lethal De Novo LQT-3 Mutation in a Newborn with Distinct Molecular Pharmacology and Therapeutic Response
2007

A Newborn with a Dangerous SCN5A Mutation and Its Treatment

Sample size: 1 publication 10 minutes Evidence: high

Author Information

Author(s): Bankston John R., Yue Minerva, Chung Wendy, Spyres Meghan, Pass Robert H., Silver Eric, Sampson Kevin J., Kass Robert S.

Primary Institution: Columbia University Medical Center

Hypothesis

Can a specific SCN5A mutation in a newborn lead to distinct therapeutic responses to sodium channel blockers?

Conclusion

The study highlights the severe impact of the SCN5A F1473C mutation on cardiac function in newborns and the importance of personalized treatment strategies.

Supporting Evidence

  • The F1473C mutation caused a significant increase in late sodium current.
  • The patient exhibited extreme QT prolongation and differential responses to sodium channel blockers.
  • Mexiletine and ranolazine effectively inhibited the mutation-induced inward current during repolarization.
  • Computational modeling showed that the mutation significantly prolonged action potential duration.

Takeaway

A baby had a special heart mutation that made their heart beat too slowly, but doctors found a way to help them feel better with medicine.

Methodology

The study involved genetic sequencing, patch clamp analysis of Na+ channels, and clinical monitoring of the newborn's heart condition.

Limitations

The computational model used was based on adult cardiac physiology, which may not accurately reflect infant heart function.

Participant Demographics

The participant was a full-term newborn infant boy with no family history of arrhythmias.

Statistical Information

P-Value

1.5e-05

Statistical Significance

p<1.5e-05

Digital Object Identifier (DOI)

10.1371/journal.pone.0001258

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication